Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 23, 2011

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
PROCEDURE

Acute Normovolemic Hemodilution

A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB \< 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB \<7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering West Harrison, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01442051 - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter